| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374357 | Bioorganic & Medicinal Chemistry Letters | 2011 | 5 Pages |
Abstract
This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Lyn H. Jones, Helen Baldock, Mark E. Bunnage, Jane Burrows, Nick Clarke, Michele Coghlan, David Entwistle, David Fairman, Neil Feeder, Craig Fulton, Laura Hilton, Kim James, Rhys M. Jones, Amy S. Kenyon, Stuart Marshall, Sandra D. Newman, Rachel Osborne,